

# Feline HCM Diagnostic Resource List

## Industry partners for HCM screening and diagnostics\*

### Screening (NT-proBNP Testing)

---

#### IDEXX Laboratories – SNAP Feline proBNP

- In-clinic point-of-care NT-proBNP test
- Helps assess cardiac risk and differentiate cardiac vs. respiratory disease

#### Antech Diagnostics

- Reference lab NT-proBNP testing and diagnostic support
- Integrated lab and imaging ecosystem

#### BioNote – Vcheck Feline NT-proBNP

- Quantitative point-of-care NT-proBNP assay
- Supports screening and monitoring

### Further Diagnostics (POCUS, Echocardiography & Cardiology Support)

---

#### Sound (Powered by Antech)

- Veterinary ultrasound systems and imaging solutions
- Training and cardiology imaging support

#### ONCURA Partners Diagnostics

- Diagnostic support and laboratory services
- Growing presence in specialty and GP diagnostic workflows

#### Butterfly Network (Butterfly iQ+)

- Handheld ultrasound device for point-of-care imaging
- App-based workflow

#### Esaote VET

- Dedicated veterinary ultrasound systems
- Strong cardiology imaging capabilities

#### Mindray Animal Medical

- Cost-effective ultrasound systems
- Cardiac presets for general practice use

#### IDEXX Telemedicine / Imaging Support

- Remote cardiology consults and interpretation
- Integrated digital imaging ecosystem

#### Antech Imaging Services

- Teleradiology and cardiology interpretation
- AI-supported imaging tools

#### Vet.CT

- Global teleradiology and specialist consult service

#### CVCA Cardiac Care for Pets

- Echocardiography and case management support

\*This list is provided for reference only. PRN Pharmacal is not affiliated with, endorsed by, or compensated by any of the diagnostic companies mentioned. We encourage you to research and evaluate each option independently to determine which diagnostic partner best aligns with your practice's needs, workflow, and patient population.

# Helping cat owners at home

## Tools your clients can use to monitor breathing\*

Normal resting breathing rate for a cat is 15–30 breaths per minute while sleeping. Increased breaths per minute could indicate cardiovascular issues. Here are three tools cat owners can use at home to track their cat's breathing.

### Sleeping Respiratory Rate (SRR) Monitors

#### For Android Devices: Pet Breath Counter

- Automated breathing counter
- Available for download through Google Play

#### For Apple Devices: Cat Breath Monitor

- Tracks breaths per minute
- Can be installed through the App Store

#### Maven Cat Respiratory Tracker

- This sensor attaches to a cat's collar and tracks breathing automatically
- Available for purchase online at [maven.pet/cat-respiratory-rate-tracker](https://maven.pet/cat-respiratory-rate-tracker)

\*PRN Pharmacal is not affiliated with, endorsed by, or compensated by any of the SRR monitors listed or their respective companies.

**IMPORTANT SAFETY INFORMATION:** Do not use Felycin<sup>®</sup>-CA1 in cats with diabetes mellitus. Discontinue immediately if a cat receiving Felycin-CA1 is diagnosed with diabetes mellitus. Do not administer in cats with pre-existing liver disease. Administration of Felycin-CA1 with drugs that inhibit cytochrome P-450 3A4 or P-glycoprotein, such as calcium channel blockers, amiodarone, azoles, or cyclosporine, may increase risk for toxicity. Use caution when administering in cats with the MDR1 mutation or when administering concomitantly with another P-gp substrate. Treatment with Felycin-CA1 could impact the cat's ability to mount an adequate immune response to vaccinations.

The use of Felycin-CA1 in cats with viral disease like feline viral rhinotracheitis has not been evaluated. The safety and effectiveness of Felycin-CA1 has not been evaluated in cats with other cardiomyopathy phenotypes, in cats receiving beta blockers or corticosteroids, in cats with kidney disease, hyperthyroidism, or other significant systemic disease. The effectiveness of Felycin-CA1 has not been evaluated in sexually intact cats, therefore, should not be used in animals intended for breeding.

Treatment with Felycin-CA1 has been associated with the elevation of the transaminase enzymes, which include alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Bloodwork should be repeated 1 to 2 months following initiation of treatment, and every 6-12 months thereafter. Discontinue treatment if transaminase values exceed 2X the upper limit of normal (ULN), if other liver enzymes besides ALT or AST are elevated, or if clinical signs of liver dysfunction are noted.

The most frequently observed adverse reactions in cats treated with Felycin-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions observed were lethargy, vomiting, diarrhea, and inappetence.

For use only in otherwise healthy cats with subclinical HCM in the absence of other causes of compensatory myocardial hypertrophy (e.g. systemic hypertension), current or historic symptoms of congestive heart failure, arterial thromboembolism, and severe LV outflow tract obstruction.

Not for human use. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans. Pregnant and breastfeeding women should avoid contact with Felycin-CA1. People with known hypersensitivity to sirolimus should administer Felycin-CA1 with caution.

Keep Felycin-CA1 in a secure location out of reach of dogs, cats and other animals to prevent accidental ingestion or overdose.

Felycin-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-604. See prescribing information for complete details regarding adverse events, warnings, and precautions.